Zobrazeno 1 - 10
of 242
pro vyhledávání: '"L, Fernández Salazar"'
Autor:
M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i50-i54
Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8acd9ed996ae8e4fcd0df9c8a1758fb8
https://doi.org/10.1093/ecco-jcc/jjac190.0037
https://doi.org/10.1093/ecco-jcc/jjac190.0037
Autor:
M Baldan-Martin, M Azkargorta, I Lloro, I Soleto Fernández, M Orejudo, C Ramírez, S García, J Mercado, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i268-i271
Background Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e323bc39c240e3927d99b4b88bfb294
https://doi.org/10.1093/ecco-jcc/jjac190.0236
https://doi.org/10.1093/ecco-jcc/jjac190.0236
Autor:
M Baldan-Martin, I Lloro, M Azkargorta, C Ramírez, I Soleto Fernández, M Orejudo, S García, J Mercado, C H Gordillo, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i202-i204
Background Inflammatory bowel disease (IBD) is a complex multi-factorial disease characterized by chronic inflammation of the gastrointestinal tract. Despite significant efforts to understand the pathogenetic mechanisms of IBD, the elucidation of its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90b3a6be66a338bc85912e84970b9d2e
https://doi.org/10.1093/ecco-jcc/jjac190.0166
https://doi.org/10.1093/ecco-jcc/jjac190.0166
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Garcia-Alvarado, J Barrio, M Sierra-Ausin, L Arias, L Fernández-Salazar, A Fuentes Coronel, L Arias García, F J García-Alonso, M García-Prada, J Legido, J G Sánchez-Hernández, F Muñoz
Publikováno v:
Journal of Crohn's and Colitis. 16:i416-i418
Background Ustekinumab is an effective drug in Crohn′s Disease (CD) and most frequently used dose is subcutaneous (sc), 90 mg /, 8 weeks. With the usual sc doses (90 mg every, 8–12 weeks) some patients will only partially respond or experience se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02aab67af34e00577a7ce6f053bf9ecb
https://doi.org/10.1093/ecco-jcc/jjab232.560
https://doi.org/10.1093/ecco-jcc/jjab232.560
Autor:
M Calafat Sard, I Pascual, P Nos, J Barrio, A Gutiérrez, M D Martín-Arranz, E Ricart, F Gomollón, M Sierra Ausín, J M Huguet, J Guardiola, I Vera, P Varela, E Iglesias, E Garcia-Planella, L de Castro, M F García Sepulcre, B Sicilia, L Fernández-Salazar, X Calvet, F Muñoz, S García-López, F Bermejo, L Ramos, P Martínez Montiel, R Lorente, J L Cabriada, M Piqueras, I Marín-Jiménez, M Esteve, F Mesonero, E Sesé, J P Gisbert, L Márquez, D Busquets, R Pajares, F Cañete, M Mañosa, E Domènech
Publikováno v:
Journal of Crohn's and Colitis. 17:i766-i767
Background The use of ustekinumab (UST) and vedolizumab (VDZ) as first line therapy for inflammatory bowel disease (IBD) is increasing due to safety reasons and contraindications of anti-TNFs. However, there are no studies evaluating their efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33fe84d94dea3853b1770f3ecc70d8fc
https://doi.org/10.1093/ecco-jcc/jjac190.0764
https://doi.org/10.1093/ecco-jcc/jjac190.0764
Introduction: Management of Helicobacter pylori infection (H. pylori) re-quires co- treatment with proton pump inhibitors (PPIs) and the use of an- tibiotics to achieve successful eradicationAims & Methods: To evaluate the role of PPIs in the eradica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::f8ae16678f84f174ed26023129768260
https://www.bib.irb.hr/1246007
https://www.bib.irb.hr/1246007
Introduction: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth.Aims & Methods: International multicenter prospective non-intervention-al registry aimed to evaluate the deci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::b4ea272a4c2c05a287e8077f8a741531
https://www.bib.irb.hr/1245964
https://www.bib.irb.hr/1245964
Introduction: Introduction: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT, i.e., PPIs plus high amoxicillin doses) when prescribed for H. pylorifirst-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::1829f9c70cac8bdabd30957fc1aa037f
https://www.bib.irb.hr/1246002
https://www.bib.irb.hr/1246002
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.